Evofem Biosciences amends debt maturity terms with Adjuvant
EVFM•Evofem Biosciences amended its agreement for Adjuvant convertible promissory notes on October 9, setting maturity at December 1, 2026.
1. Amended maturity terms
The amended agreement allows earlier repayment upon a change of control at Adjuvant’s election or acceleration under the agreement. Prepayment before December 1, 2026, requires Adjuvant’s prior written consent.
